Genmab — November 2020
-
Markedet er tydeligvis ikke blevet imponeret af gen1046. Og det kommer CMD næppe til at ændre på. Stable Disease. Hvad fa'en kan man bruge det til? Markedet vil ha' cure. Nogle komplette responser. Vi må håbe på epco på ASH, da der nok ikke kommer guldkorn om det i morgen.
-
Janssen Submits Applications in U.S. and EU Seeking Approval of DARZALEX FASPRO
(daratumumab and hyaluronidase-fihj)/DARZALEX
(daratumumab) Subcutaneous (SC) Formulation in Combination With Pomalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma -
Hvis man sammenligner med first in human med Atezolizumab, så ser Gen1046 sådan set meget overbevisende ud (PR 5.9%, med SD 17.6%)https://www.sciencedirect.com/science/article/pii/S1525730420301480
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind